000128648 001__ 128648
000128648 005__ 20240228145543.0
000128648 0247_ $$2doi$$a10.1200/JCO.2017.73.0085
000128648 0247_ $$2pmid$$apmid:28771378
000128648 0247_ $$2ISSN$$a0732-183X
000128648 0247_ $$2ISSN$$a1527-7755
000128648 0247_ $$2altmetric$$aaltmetric:23400027
000128648 037__ $$aDKFZ-2017-04664
000128648 041__ $$aeng
000128648 082__ $$a050
000128648 1001_ $$aRadujkovic, Aleksandar$$b0
000128648 245__ $$aPretransplant Vitamin D Deficiency Is Associated With Higher Relapse Rates in Patients Allografted for Myeloid Malignancies.
000128648 260__ $$aAlexandria, Va.$$bAmerican Society of Clinical Oncology$$c2017
000128648 3367_ $$2DRIVER$$aarticle
000128648 3367_ $$2DataCite$$aOutput Types/Journal article
000128648 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1510835298_26038
000128648 3367_ $$2BibTeX$$aARTICLE
000128648 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000128648 3367_ $$00$$2EndNote$$aJournal Article
000128648 520__ $$aPurpose Vitamin D (VitD) deficiency is common in patients with hematologic malignancies undergoing allogeneic transplantation (alloSCT), but its prognostic relevance is unclear. Patients and Methods The impact of pretransplant VitD status on overall survival, relapse mortality, and nonrelapse mortality was investigated retrospectively in a cohort of 492 patients undergoing alloSCT at our center from 2002 to 2013. VitD deficiency was defined as a serum level of 25-hydroxyvitamin D3 < 20 ng/mL (equivalent to < 50 nM) before alloSCT and was assessed using accredited laboratory methods and a standard chemiluminescent immunoassay. Results were validated in an independent cohort of 398 patients diagnosed with myeloid malignancies. Results A total of 396 (80%) and 348 (87%) patients had VitD deficiency before alloSCT in the training and validation cohort, respectively. In the training cohort, VitD deficiency was significantly associated with inferior overall survival (hazard ratio [HR], 1.78; P = .007) in multivariable analysis. This was due to a higher risk of relapse (HR, 1.96; P = .006) rather than nonrelapse mortality. A significant association of pretransplant VitD deficiency with higher relapse rates was observed only in patients diagnosed with myeloid (HR, 2.55; P = .014) but not with lymphatic diseases (HR, 1.60; P = .147). A similar impact of pretransplant VitD deficiency on relapse risk in myeloid diseases was also observed in an independent patient cohort (HR, 2.60; P = .017). Validation of the effect of VitD deficiency on relapse in patients with myeloid malignancies was successful. Conclusion Pretransplant VitD deficiency was associated with a higher risk of relapse in patients allografted for myeloid malignancies. Prospective studies on VitD status and correction of VitD deficiency in the setting of alloSCT are highly warranted.
000128648 536__ $$0G:(DE-HGF)POF3-319H$$a319H - Addenda (POF3-319H)$$cPOF3-319H$$fPOF III$$x0
000128648 588__ $$aDataset connected to CrossRef, PubMed,
000128648 7001_ $$aKordelas, Lambros$$b1
000128648 7001_ $$0P:(DE-He78)5a7a75d1b29b770f98f1bb2062fc3df9$$aKrzykalla, Julia$$b2
000128648 7001_ $$aBeelen, Dietrich W$$b3
000128648 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b4
000128648 7001_ $$0P:(DE-He78)8dc0876dc3ed1862337d98842984727d$$aLehners, Nicola$$b5$$udkfz
000128648 7001_ $$aSchmidt, Katharina$$b6
000128648 7001_ $$aDreger, Peter$$b7
000128648 7001_ $$aLuft, Thomas$$b8
000128648 773__ $$0PERI:(DE-600)2005181-5$$a10.1200/JCO.2017.73.0085$$gVol. 35, no. 27, p. 3143 - 3152$$n27$$p3143 - 3152$$tJournal of clinical oncology$$v35$$x1527-7755$$y2017
000128648 909CO $$ooai:inrepo02.dkfz.de:128648$$pVDB
000128648 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5a7a75d1b29b770f98f1bb2062fc3df9$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000128648 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000128648 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8dc0876dc3ed1862337d98842984727d$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000128648 9131_ $$0G:(DE-HGF)POF3-319H$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vAddenda$$x0
000128648 9141_ $$y2017
000128648 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000128648 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CLIN ONCOL : 2015
000128648 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000128648 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000128648 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000128648 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000128648 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000128648 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000128648 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000128648 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000128648 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000128648 915__ $$0StatID:(DE-HGF)9920$$2StatID$$aIF >= 20$$bJ CLIN ONCOL : 2015
000128648 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000128648 9201_ $$0I:(DE-He78)G170-20160331$$kG170$$lExperimentelle Therapien hämatologischer Neoplasien$$x1
000128648 980__ $$ajournal
000128648 980__ $$aVDB
000128648 980__ $$aI:(DE-He78)C060-20160331
000128648 980__ $$aI:(DE-He78)G170-20160331
000128648 980__ $$aUNRESTRICTED